Open non-comparative trial of the drug impase for treatment of erectile dysfunction
- Authors: Mazo EВ1, Gamidov SI1, Ovchinnikov RI1
-
Affiliations:
- Issue: No 3 (2003)
- Pages: 28-31
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/274926
- ID: 274926
Cite item
Full Text
Abstract
Clinical efficacy and safety of the drug impase in erectile dysfunction (ED) were studied in 30 patients with ED of various genesis (mean age 52.0914.75 years). IIED questionnairing was employed, combined andrological examination and standard laboratory investigations. Impase was taken 1 tablet a day each other day for 12 weeks irrespective of the intercourse. The number of attempted intercourses was at least 4 times a month. The treatment efficacy was assessed by changes of IIED parameters, subjective and objective effects. ED was
psychogenic in 5 (16.7%) patients, organic in 25 (83.3%) patients. Blood hormones were normal for age in all the patients. According to IIED, "erectile function" mean score after 12 week treatment rose from 18.89±5.25 to 22.50±4.86. In 11 (36.7%), 4 (13.3%), 5 (16.7%) patients the response was rated as excellent, good and satisfactory, respectively. No response was stated in 10 (33.3%) patients. Side effects were absent. Tolerance and safety were excellent. Thus, efficacy of impase therapy varied from 60 to 66.7% depending on ED etiology and pathogenesis. Cost-efficacy, absence of side effects, possible parallel therapy of concurrent diseases, course administration are advantages of the treatment.
psychogenic in 5 (16.7%) patients, organic in 25 (83.3%) patients. Blood hormones were normal for age in all the patients. According to IIED, "erectile function" mean score after 12 week treatment rose from 18.89±5.25 to 22.50±4.86. In 11 (36.7%), 4 (13.3%), 5 (16.7%) patients the response was rated as excellent, good and satisfactory, respectively. No response was stated in 10 (33.3%) patients. Side effects were absent. Tolerance and safety were excellent. Thus, efficacy of impase therapy varied from 60 to 66.7% depending on ED etiology and pathogenesis. Cost-efficacy, absence of side effects, possible parallel therapy of concurrent diseases, course administration are advantages of the treatment.
References
- Feldman H. A., Goldstein I., Hatzkhristou D. G. et al. J. Urol. (Baltimore) 1994; 151: 54-61.
- Goldstein I., Lite T. F., Padma-Nathan H. et al. N. Engl. J. Med. L998; 338: 1397-1404.
- Morales A., Gingell C., Collins M., et al. Int. J. lmpot. Res. 1998; 10: 69-74.
- Padma-Nathan H., Steers W. D., Wicker P. A. Int. J. Clin. Pract. 1998; 52: 375-379.
- Wespes E., Amar E. et al. Eur. Urol. 2002; 41: 1-5.
- Боровская Т. Г., Лоскутова О. П., Эпштейн О. И., Зак М. С. Бюл. экспер. биол. 2001; Прил. 3: 52-53.
- Smolenov I. V., Dygai A. M., Epstein О. I. et al. Pharmacologist 2002; 44 (2, suppl. 1): A167.
- Петров В. И., Дыгай А. М., Мартюшев А. В. и др. В кн.: Материалы Медико-фармацевтического форума. М.; 2002. 86-87.
Supplementary files
